Cadrenal Therapeutics (NASDAQ: CVKD) has announced clinical trial initiation plans for its lead late-stage candidate, tecarfarin, for the treatment of patients with end-stage kidney disease (ESKD) transitioning to dialysis.
According to Cadrenal, enrollment is to commence later this year and will include patients with and without atrial fibrillation (AFib).
In a statement, Quang X. Pham, chairman and CEO of Cadrenal, commented, “There is a critical need for safe, effective anticoagulants for use in ESKD patients. Tecarfarin’s orphan drug and fast-track designations in ESKD patients with AFib underscores this need, and we are excited to advance this program.”
He added, “This study will be an important step forward for the continued development of tecarfarin in ESKD and in other areas with real opportunities to improve patient outcomes with a potentially better vitamin K antagonist.”
